Laquinimod (sodium)

Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4].

Product Specifications

CAS Number

[248282-07-7]

Product Name Alternative

ABR-215062 (sodium)

UNSPSC

12352005

Hazard Statement

H302-H332-H341-H360-H362

Target

Apoptosis; NF-κB

Type

Reference compound

Related Pathways

Apoptosis; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/laquinimod-sodium.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2Cl)N(CC)C3=CC=CC=C3.[Na]

Molecular Formula

C19H17ClN2NaO3

Molecular Weight

379.79

Precautions

P260-P261-P263-P264-P270-P271-P280-P304+P340-P330-P405-P501

References & Citations

[1]Jan Thöne, et al. Laquinimod in the treatment of multiple sclerosis: a review of the data so far. Drug Des Devel Ther. 2016 Mar 14;10:1111-8.|[2]Brück W, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124 (3) :411-24.|[3]Schulze-Topphoff, Ulf., et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One (2012), 7 (3), e33797.|[4]Toubi E, et al. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. J Neuroimmunol. 2012 Oct 15;251 (1-2) :45-54.